Agree! Stoney's are too. Ya know actually, that would be a great name for a line of shoes. For skate-boarders or the like. Stoney!!!! Get on Alibaba's website and order us a couple container-fulls of some cool looking lightweight shoes. I'll design the label. They'll cost us $2 and we'll sell them for $179. $129 for Black Friday. (2023 if we can get em by then) "Stoney's... They're more than a shoe, they're a lifestyle".
Iovance Biotherapeutics provides an update conference call 04:55 IOVA Conference call to discuss data presented at the SITC Annual Meeting will be held on November 13 TODAY!!!!!!at 5:30 pm. <----------- IS THE NEWS GOOD?. Stk has come in a little bit - I think. I have to double check maybe $21
Stock was down 9% on Fri- I missed this) Iovance Biotherapeutics announces clinical data for LN-145 at SITC 2021 meeting 07:44 IOVA Iovance Biotherapeutics announced additional clinical data for its tumor infiltrating lymphocyte, TIL, therapy LN-145 in patients with metastatic non-small cell lung cancer, NSCLC, who enrolled in Cohort 3B of the ongoing basket study IOV-COM-202. The results are available in a poster at the Society for Immunotherapy of Cancer, SITC, Annual Meeting, November 12-14, 2021, Washington, D.C. and virtual. The results demonstrate the feasibility of TIL cell therapy in heavily pre-treated patients with NSCLC, and warrant continued investigation of LN-145 as a single-agent and in combination in patients with mNSCLC in ongoing Iovance clinical studies IOV-LUN-202 and IOV-COM-202. Following one-time treatment with LN-145 monotherapy, the overall response rate is 21.4% in the full analysis set and 25% in the efficacy-evaluable set, including one complete response and five partial responses. Two responders, including the CR, had PD-L1 negative tumors and two responders had tumors with KRAS mutations. One complete response and one partial response are ongoing at 20.7 months and 3.0 months, respectively, at a median study follow up of 9.8 months. The treatment-emergent adverse event profile is consistent with the underlying disease and known adverse event profiles of non-myeloablative lymphodepletion and IL-2. The heavily pre-treated patients in Cohort 3B had received a median of 2 prior therapies. All patients had progressed on prior immune checkpoint inhibitor therapy and all six responders received prior chemotherapy. TIL were most commonly grown and manufactured from tumor samples resected from the lung. Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, "We are pleased to present our clinical data for LN-145 in metastatic non-small cell lung cancer to the physician community at SITC. There remains a very significant unmet need to increase response rates and prolong survival in the second-line non-small cell lung cancer treatment setting. The data for LN-145 in this signal-finding cohort demonstrated the potential for TIL in metastatic non-small cell lung cancer across a diverse set of patients and informed our ongoing IOV-LUN-202 clinical study in second-line lung cancer. Iovance is committed to advancing both TIL alone and TIL combinations to address multiple non-small cell lung cancer patient populations." Iovance is currently enrolling patients in the IOV-LUN-202 clinical study to investigate LN-145 in second-line mNSCLC where patients have progressed on prior ICI and chemotherapy. CC to save?
I don't see where they say the size of the study so one complete response sounds bad! I dunno this could go south.
Marijuana players dominated top performers in healthcare this week ahead of a Republican-led attempt for federal legalization of cannabis in the U.S. Meanwhile, less than favorable quarterly earnings hurt decliners. However, the healthcare stocks ended the week in positive territory with a ~0.6% gain to become the second-best performing sector in the S&P 500, narrowly beating the ~0.3% drop in the broader index. Among stocks with more than $2B market capitalization and over 100K average daily volume over the past five sessions, Canopy Growth(NASDAQ:CGC)surged the most with a ~29.5% gain. Its local rivals, Aurora Cannabis(NASDAQ:ACB)and Tilray(NASDAQ:TLRY), were not far behind, rising ~27.6% and ~20.9%, respectively to group among the top five performers. The resurgence of cannabis players comes at a time Global X Cannabis ETF(NASDAQ:POTX)and AdvisorShares Pure US Cannabis ETF(NYSEARCA:MSOS)remain sharply lower from their February peak and precedes the launch of a Republican bill on Monday to legalize marijuana at the federal level. The proposed legislation led by Rep. Nancy Mace (R-SC) is said to have a softer regulatory approach compared to the bill introduced by Senate Majority Leader Chuck Schumer (D-N.Y.) in July, Bloomberg reported, citing people who have seen the draft. Citing the recent underperformance of U.S. MSOs and the latest legislative move favoring the industry, Cantor Fitzgerald analyst Pablo Zuanic noted: “The tide will likely lift all boats.” Turning to other top gainers of the week, Apollo Medical Holdings(NASDAQ:AMEH) climbed ~27.8%, making its entry to the top-performer list for the second week in a row. Driven by an earnings-led rally, Alhambra, California-based healthcare management company, has gained ~54.9% for the past 30-day period. Meanwhile, Apellis Pharmaceuticals(NASDAQ:APLS)ended ~27.4% higher over the week as the company reiterated its timeline to submit a marketing application to the FDA for a potential eye disease therapy.
Stoney!!!! I saw a new Grand Wagoneer yesterday. They have TV screens for every seat! What are we becoming? Why are we raising brain-dead prodigy? Screens at home, screens on the phone, screens in the car! Is it the Aliens Stoney?
It's damn ugly Van. I was counting on this release to drive up interest in my model but they used no wood panels. It;s not a good looking car they go on andon about being made in America<-- But it's ugly Made In America. The biggest news story not reported to much last week is that BMW which owns Rolls Royce is getting into the baby Nuke game-! According to a press releasei ssued by Rolls-Royce, one of the 16 reactors it’s planning to build will take up the space of two football fields—about a tenth of the size of a conventional reactor—while providing enough power for 1 million homes. Per the press release, the business will now move on to the preliminary stages of starting production, including identifying factories where it could possibly produce modules for the on-site assembly of the reactors.
Very tough grind finding anything. But wait there was a list of ten low priced stks that looked good and these guys just missed that list but hey sounded interesting Flat bed Trucking. Analysts are busy identifying sleeper picks from the infrastructure bill. Baird has Oshkosh (OSK+0.2%) on its attractive list, Cowen names Landstar System (LSTR+0.1%) and Daseke (DSKE+2.0%) as infrastructure winners and Bernstein is pointing to Trimble (TRMB+1.1%) and United Rentals (URI+1.3%). DSKE- Chart Interesting for sure0 I see $12 Daseke, Inc. 10.07 0.28(+2.86%) 4:00 PM 11/12/21 Daseke reports Q3 adjusted EPS 43c, consenus 32c 10/22 DSKE Reports Q3 revenue $424.6M, consensus $423.28M. "We are pleased to report another quarter of strong operating and financial results, as Daseke continued to decisively execute against the backdrop of a strong freight environment. Once again, we demonstrated the strength of our operating model, effectively flexing our 'asset-right' fleet in order to service the needs of our customers in this unprecedented market. Prospectively, we plan to deliver meaningful value to our shareholders by continuing to leverage our scale and our differentiated capabilities, while also maintaining a keen focus on advancing our operational improvement initiatives," said Jonathan Shepko, Chief Executive Officer of Daseke. Daseke price target raised to $12 from $10 at Craig-Hallum 08/03/21 DSKE Craig-Hallum analyst Ryan Sigdahl raised the firm's price target on Daseke to $12 from $10 and keeps a Buy rating on the shares. Sigdahl believes the company and stock are at an inflection point, and feels Daseke is benefiting from a cyclical recovery plus continued progress on its operational improvement strategy, the analyst tells investors in a research note. He thinks the right management team is in place, great progress has been made on improving operational efficiencies with a lot of upside still to come.
Yeah but loyal readers of The Garden knew. You reported it! Early last week. Regarding the Wagoneer.... I don't care about the wood panels, my point was about the TV screens. They all have them now, it's ridiculous. Why even put in windows if kids are going to spend their entire lives glued to all this bs?! I mean seriously. Glass is heavy. In the race for more fuel efficiency, delete the friggin' windows. THEN: NOW: Whaaat-ever...